Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Compass Therapeutics (CMPX) EBITDA Margin (2024)

Compass Therapeutics' EBITDA Margin history spans 1 years, with the latest figure at 1538.47% for Q2 2024.

  • On a quarterly basis, EBITDA Margin changed N/A to 1538.47% in Q2 2024 year-over-year; TTM through Jun 2025 was 7262.24%, a 175329.0% decrease, with the full-year FY2024 number at 5788.47%, changed N/A from a year prior.
  • EBITDA Margin hit 1538.47% in Q2 2024 for Compass Therapeutics.
  • Over the last five years, EBITDA Margin for CMPX hit a ceiling of 1538.47% in Q2 2024 and a floor of 1538.47% in Q2 2024.